Hyperoxaluria
No Results
No Results
processing….
The normal upper level of urinary oxalate excretion is 40 mg (440 µmol) in 24 hours. Men have a slightly higher normal value (43 mg/d in men vs 32 mg/d in women), but this is primarily due to larger body habitus and larger average meal size rather than to any real intrinsic metabolic difference. Stone formation risk probably depends more on absolute total oxalate excretion and concentration than on arbitrary normal values.
Reflecting these normal values, the usual definition of hyperoxaluria is urinary oxalate excretion that exceeds 40 mg/day. The 4 main types of hyperoxaluria are the following [1, 2] :
Primary hyperoxaluria (types, I, II and III)
Enteric hyperoxaluria
Dietary hyperoxaluria
Idiopathic or mild hyperoxaluria
An alternative definition of hyperoxaluria that corrects for size differences is 30 mg of urinary oxalate per 24 hours per gram of excreted creatinine. Still, the relative concentration of oxalate is probably more significant than either of these definitions acknowledges.
For other discussions on nephrolithiasis, see the topics Nephrolithiasis, Pediatric Nephrolithiasis, Imaging Urinary Calculi, Hypercalciuria, and Hypocitraturia.
For patient education resources, see the Kidneys and Urinary System Center, as well as Kidney Stones.
Oxalate is an organic salt with the chemical formula of C2 04. At physiological pH levels, oxalate forms a soluble salt with sodium and potassium; however, when combined with calcium, it produces an insoluble product termed calcium oxalate, which is the most common chemical compound found in kidney stones.
Oxalate is absorbed primarily from the colon, but it can be absorbed directly from anywhere in the intestinal tract. In addition, oxalate is created from endogenous sources in the liver as part of glycolate metabolism. In the kidney, oxalate is secreted in the proximal tubule via 2 separate carriers involving sodium and chloride exchange.
Oxalate is normally produced in plants, primarily in their leaves, nuts, fruit, and bark. The amount of oxalate manufactured depends not only on the particular variety of plant but also on the soil and water conditions in which it grows. In general, plants that are grown in fields with a high concentration of ground water calcium have higher concentrations of oxalate. This is one reason why precisely calculating dietary oxalate is difficult.
Oxalate content within the same plant species can vary widely. For example, potatoes contain oxalate levels of 5.5-30 mg per 100 g, broccoli has levels of 0.3-13 mg per 100 g, and wheat bran has levels of 58-524 mg per 100 g.
Plants use oxalate as a calcium sink. Any excess calcium absorbed by the plant from ground water is extracted from the plant’s tissue fluid by the oxalate in the leaves, fruits, nuts, or bark. Eventually, the plant sheds these structures. When humans eat these plant products, they also ingest a variable quantity of oxalate. Food products from animal sources have virtually no oxalate content.
Oxalate is involved in various metabolic and homeostatic mechanisms in fungi and bacteria and may play an important role in various aspects of animal metabolism, including mitochondrial activity regulation, thyroid function, gluconeogenesis, and glycolysis. Interestingly, oxalate was first discovered in animals when sheep became ill after eating vegetation later found to have high oxalate content.
In humans, however, oxalate seems to have no substantially beneficial role and acts as a metabolic end-product, much like uric acid. If not for oxalate’s high affinity for calcium and the low solubility of calcium oxalate, oxalate and oxalate metabolism would be of little interest. Urinary oxalate is the single strongest chemical promoter of kidney stone formation. Ounce for ounce, it is roughly 15-20 times more potent than excess urinary calcium.
Daily oxalate intake in humans is usually 80-120 mg/d; it can range from 44-350 mg/d in individuals who eat a typical Western diet. The solubility of oxalate at body temperature is only approximately 5 mg/L at a pH of 7.0.
Among persons with stones, urinary oxalate levels tend to be significantly higher in summer than in winter. This may be due to the increased consumption of seasonal foods naturally high in oxalate (see the image below). In addition, the average mean urinary oxalate excretion in persons with calcium stones tends to be higher than in individuals without calcium stones.
High levels of oxalate in the system can produce various health problems, particularly kidney stone formation.
The 4 main types of hyperoxaluria—primary hyperoxaluria (types I and II), enteric hyperoxaluria, dietary hyperoxaluria, and idiopathic or mild hyperoxaluria—are the results of different pathophysiologic processes (see below).
This rare form of hyperoxaluria is due exclusively to a genetic defect that causes a loss of specific enzymatic activity. With the normal metabolic pathway blocked, the alternative pathway that leads to oxalate production as an end-product of glycolate metabolism becomes extremely active, resulting in extremely high oxalate production. [3]
Type I hyperoxaluria is more common than type II: it occurs in 1 per 120,000 live births and is transmitted as an autosomal recessive trait. In primary hyperoxaluria type I, the missing enzyme is alanine-glyoxylate aminotransferase (ie, the AGT gene) and is normally found only in the hepatic peroxisomes. This enzyme is necessary to detoxify glyoxylate. [4] When alanine-glyoxylate aminotransferase is lacking, oxalate production soars. [1]
Pyridoxine (vitamin B-6) is a cofactor in this chemical pathway, which normally converts glyoxylic acid (C2 H2 O3) to glycine. [5] When the pathway is blocked because of a deficiency or absence of this enzyme, the result is high levels of glycolic and oxalic acid, which readily convert to oxalate. Oxalate is then excreted in the urine, which leads to nephrocalcinosis and the eventual development of end-stage renal failure, usually in childhood.
In a retrospective cohort study of 155 patients with primary hyperoxaluria type I, Harambat et al (2010) found that, among patients who underwent DNA analysis, the p.Gly170Arg AGXT mutation was the most common and was associated with a better prognosis. The median age at end-stage renal disease was 47 years in p.Gly170Arg homozygotes and 35 years in heterozygotes. Among patients with other mutations, the median age at end-stage renal disease was 21 years. [6]
Type II hyperoxaluria is much less common than type I. In primary hyperoxaluria type II, the missing enzyme is D-glyceric dehydrogenase, which can be detected in leukocyte preparations. This deficiency promotes the conversion of glyoxylate to oxalate. [4]
The 2 types of primary hyperoxaluria result in approximately the same degree of hyperoxaluria. However, end-stage renal disease is slightly less common in patients with type II primary hyperoxaluria. Pyridoxine is generally not effective in patients with type II primary hyperoxaluria.
Recently, a type III primary hyperoxaluria, due to mutations in the HOGA1 (formerly DHDPSL) gene has been described. [7, 8] This may result in an increase in mitochondrial 4-hydroxy-2-oxoglutarate aldolase activity and excess oxalate production. Type III has been reported as a possible cause in patients with idiopathic calcium oxalate stones. However, no end-stage renal disease has been reported, suggesting that this type may be a milder form of primary hyperoxaluria. [7, 9, 10, 11]
Enteric hyperoxaluria accounts for approximately 5% of all cases of hyperoxaluria. It is due to a gastrointestinal problem usually associated with chronic diarrhea. Malabsorption from any cause can result in enteric hyperoxaluria. Such causes include intestinal bacterial overgrowth syndromes, fat malabsorption, chronic biliary or pancreatic disease, various intestinal bypass surgical procedures, inflammatory bowel disease, or any medical condition that causes chronic diarrhea. [12]
The basic mechanism is competition for the available ingested calcium, the leading intestinal oxalate-binding agent. Most of the bile acids produced during digestion are reabsorbed in the proximal intestinal tract. When this fails to occur, calcium and magnesium bind to these bile acids through saponification. [13] This leaves very little free calcium available for absorption or binding with oxalate in the lower intestinal tract. Without the calcium necessary to adequately bind oxalate in the intestinal tract, additional oxalate is absorbed and then excreted in the urinary tract.
Increased intestinal membrane oxalate transport and absorption may also occur through direct exposure of the intestinal lining to excess bile salts and fatty acids, which increases the oxalate permeability of the colonic mucosa. [14]
Hyperoxaluria has been reported to be the most common urinary metabolic abnormality in patients with stones who have undergone bariatric surgery. [15, 16] Oxalate absorption by the colon has been shown to increase up to 300-fold following small-bowel bypass surgery; therefore, these individuals must be screened for enteric hyperoxaluria. In some severe cases, the bypass may need to be reversed to control the hyperoxaluria. The recent proliferation of bariatric surgery cases may result in an increased prevalence of enteric hyperoxaluria in the future. [15, 16]
Previously, dietary oxalate was thought to play a relatively minor role in hyperoxaluria and to account for only 10-20% of the total urinary oxalate produced. Recent evidence suggests that dietary oxalate plays a much more important role and may be responsible for 50% of the total urinary oxalate. [17, 18, 19] In one study, dietary sources were found to be directly responsible for 80% of the total excreted oxalate.
A high intake of oxalate-rich foods (eg, chocolate, nuts, spinach) and a diet rich in animal protein can result in hyperoxaluria. Low dietary calcium intake can also result in hyperoxaluria via decreased intestinal binding of oxalate and the resulting increased absorption. Ascorbic acid can be converted in oxalate, resulting in increased urinary oxalate levels.
Many patients, perhaps as many as 80%, have an abnormal or altered cellular membrane oxalate transport mechanism, which causes abnormally high absorption of dietary oxalate.
Others may have a deficiency of Oxalobacter formigenes, an intestinal facultative anaerobic bacterium that naturally digests oxalate. When this bacterium is lost through prolonged antibiotic use or other reasons, increased intestinal oxalate absorption is likely. Some studies have shown a correlation between decreased activity of this bacterium in the intestine and hyperoxaluria and stone formation. [20, 21, 22]
Oxalobacter is relatively resistant to penicillin and sulfa but sensitive to macrolides, fluoroquinolones, and tetracyclines. Patients with calcium oxalate stones who have lost their natural intestinal Oxalobacter are found to have 40% higher average urinary oxalate levels than patients with calcium oxalate stones who have normal intestinal Oxalobacter colonies. Oxalobacter usually colonizes the intestinal tract at approximately age 3 years. Once lost, recolonizing Oxalobacter in the intestinal tract is very difficult.
Bioavailability of ingested oxalate, dietary calcium and magnesium levels, [23, 13] intestinal transit time, use of sodium cellulose phosphate (which removes calcium and magnesium from the intestine), and lack of intestinal oxalate binders can all affect oxalate absorption. Ethylene glycol ingestion and methoxyflurane exposure can also cause hyperoxaluria through a hepatic metabolic pathway. The rest are thought to be caused by metabolic or hepatic activity.
This is by far the most common variety of hyperoxaluria observed in patients with calcium oxalate stones. It may be due to a simple dietary excess of high-oxalate food sources or to increased endogenous oxalate production. While originally thought to be caused mainly by endogenous oxalate production, recent evidence suggests that up to 50% or more of urinary oxalate is related to diet.
In 1986, Baggio et al found an enhanced, altered red blood cell membrane oxalate transport mechanism in approximately 80% of patients with idiopathic kidney stones that was not present in the siblings of these patients, who did not have stones. [24] The variable response among patients to a controlled oxalate diet also suggests that a genetic component may play a role in the development of hyperoxaluria by modifying intestinal oxalate absorption.
The problem with oxalate is its strong chemical affinity for calcium and the relatively low solubility of the resulting salt. Most people have a relative supersaturation of calcium oxalate in their urine, which is kept from precipitating by various factors, including dilutional volume and specific inhibitors such as citrate. Optimizing these other risk factors has a beneficial effect on reducing calcium oxalate stone production.
Hyperoxaluria (excessive urinary oxalate) is a common abnormal finding in patients with calcium oxalate kidney stones. Some degree of excessive urinary oxalate is found in 20-30% of all patients with recurrent calcium oxalate stones. Approximately 30 million persons in the United States have kidney stone disease, and 1.2 million new cases are encountered each year. The most common type of kidney stone is calcium oxalate. Although hypercalciuria may be the more common metabolic problem, excess urinary oxalate is a much stronger promotor of urinary stone formation than excess urinary calcium.
Hyperoxaluria seems to be a greater problem in countries that are more highly developed. In Japan, an increasing incidence of calcium oxalate stone disease seems to have accompanied gradual changes in dietary trends. As animal protein and fat intake increases among the Japanese population, oxalate absorption, oxaluria, and calcium oxalate stone disease also increase. Increased dietary fat allows for an increase in calcium complexation, with fatty acids causing a mild form of enteric hyperoxaluria. Primary hyperoxaluria is more common among Muslims.
Kidney stones are more common in whites than in blacks. This is well-established and is thought to be primarily due to the difference in average socioeconomic status and dietary influences.
An intriguing study from South Africa by Lewandowski et al found that urinary oxalate excretion after a controlled oral oxalate load was much higher in whites than in blacks. [25] This was thought to be due to increased intestinal oxalate transport in the white study group.
A similar study by Rodgers and Lewandowski found that a low-calcium diet caused a statistically significant increase in urinary oxalate only in blacks. [26] The cause for these racial differences has not been determined, but genetic factors are thought to be involved.
No significant differences in mean urinary oxalate excretion levels or concentration between geriatric and younger cohorts of individuals with calcium oxalate stones have been found. [27, 28] Primary hyperoxaluria type I presents primarily as a pediatric disease, with symptoms first appearing before age 4 in nearly half of the patients. [29]
Kidney stones are 3 times more common in men than in women, but the reason for this difference is not always clear. Different reference ranges of several urinary metabolites (eg, uric acid, calcium, oxalate) illustrate the difficulties in determining the actual cause of stones in different populations. It is unknown whether the different values are the result of differences in metabolism related to the effects of sex hormones or are incidental to the known differences in dietary intake and body weight. [30]
That kidney stones are equally prevalent among males and females in childhood and in the postmenopausal age group suggests that female sex hormones may play a somewhat protective role. A study involving 4 groups of rats seems to confirm this. [31] Two groups underwent oophorectomy; a third underwent a sham surgery. One of the oophorectomized groups received supplemental estrogen and progesterone. Except for the control group, all groups were given ethylene glycol and vitamin D supplementation to induce calcium oxalate kidney stone formation.
The findings indicated that the urinary oxalate excretion rate was significantly higher in the oophorectomized group than in the groups that retained their ovaries or received supplemental female sex hormones. The renal calcium content, crystal deposition, and osteopontin levels were also higher in the oophorectomized group. The investigators concluded that female sex hormones may protect against calcium oxalate stone formation, with oxalate excretion being a key factor.
A similar study by Fan et al found the same protective benefit from estrogen. [32] Neutered rats given estrogen supplementation had lower levels of urinary and plasma oxalate and did not develop calcium oxalate crystals, even when given ethylene glycol to induce hyperoxaluria. In comparison, 88% of the rats given testosterone produced significant calcium oxalate crystals and had higher serum and urine oxalate levels, which suggests that testosterone plays a significant role in the development of calcium oxalate stones and hyperoxaluria in men. [33]
Another animal study, also by Fan et al, described significantly decreased urinary oxalate levels in both castrated rats and those treated with high-dose finasteride (Proscar), suggesting that dihydrotestosterone may be responsible for some of the differences noted in oxalate excretion between men and women. [34]
Clearly, more research would be helpful in determining the true role of sex hormones in hyperoxaluria and calcium oxalate stone disease.
Some evidence suggests that, for oxalate, the differences are due purely to body weight. [35] When this is considered and corrected with the alternative definition of 30 mg of urinary oxalate per 24 hours per gram of excreted creatinine, the results of one study showed essentially no unexplained differences.
However, a review by Gary Curhan of Harvard based on several very large series found that men have substantially higher mean urinary oxalate and uric acid levels than women in similar weight categories. This suggests that men have higher average urinary oxalate levels than women, even when weight differences are corrected. [36]
Powell et al reviewed the issue of obesity associated with kidney stone formation based on a large national database [35] and found that, in general, women who were obese and had stones tended to be at somewhat higher risk than women who were not obese who had stones. However, little, if any, difference was observed in men.
In both men and women, mean urinary oxalate levels were approximately one third higher in those who were obese and had stones than in those who were not obese and had stones. However, when urinary volume and concentration were considered, the mean average urinary oxalate concentration among men who were obese and had stones was only slightly increased; the same was not true among women who were obese and had stones.
Women have a higher response rate to pyridoxine therapy for mild and moderate hyperoxaluria disorders than men do. The reason for this discrepancy is unclear.
The mean urinary glycosaminoglycans concentration is lower in men with stones than in women with stones; this may play a role in the difference in the stone formation rate between the sexes.
The consequences of hyperoxaluria, like those of all forms of stone disease, are related to stone formation and subsequent damage to the urinary tract. These may include pain, renal obstruction, urosepsis, renal insufficiency, renal failure, and even death. Primary hyperoxaluria in particular is associated with the most serious health consequences. Approximately half of patients diagnosed with this disorder develop end-stage renal disease, and the mortality rate, particularly in infants, is high (>50%). [37]
Without treatment, the prognosis for these patients is poor. Renal failure develops in 50% of patients with primary hyperoxaluria by age 15 years and in 80% by age 30 years. Normal dialysis for uremia cannot remove enough serum oxalate to protect the kidneys and other organs from widespread calcium oxalate deposition (ie, oxalosis) and calcium oxalate stone production.
The prognosis of primary hyperoxaluria depends on early treatment and management of hyperoxaluria and associated renal deterioration. If medical treatment cannot help the patient maintain a normal oxalate level, nephrocalcinosis may develop, with subsequent renal failure. In this situation, combined liver-renal transplantation is necessary for cure. [38, 39]
The prognosis of enteric and mild hyperoxaluria is favorable if medical management and dietary modifications are followed. Periodic retesting using 24-hour urine assessments should be performed regularly to monitor compliance and treatment effectiveness.
The median age for presentation of initial symptoms related to hyperoxaluria is 5 years. Oxalate deposition can occur in other organs (eg, bones, joints, eyes, heart). In particular, bone tends to be the major repository of excess oxalate in persons with primary hyperoxaluria. Bone oxalate levels are negligible in healthy individuals. Oxalate deposition in the skeleton tends to increase bone resorption and to decrease osteoblast activity.
Because symptoms occur relatively late and are associated with serious complications, all pediatric patients who have stones should be screened for hyperoxaluria. Discovering this condition in siblings may allow earlier testing, detection, diagnosis, and preemptive therapy.
Urinary oxalate excretion is typically more than 100 mg/d in both types of primary hyperoxaluria. A liver biopsy can be helpful in determining which type of enzyme defect (alanine-glyoxylate aminotransferase or D-glyceric dehydrogenase) is present. Primary hyperoxaluria may result in renal failure due to nephrocalcinosis.
Enteric hyperoxaluria is characterized by very high urinary oxalate levels (usually 80 mg/d or more) and hypocalciuria, with urinary calcium excretion usually less than 100 mg/d. Generally, a chronic diarrheal state is present, leading to hypocitraturia and relative dehydration in addition to the hyperoxaluria. It should be considered in any patient with calcium oxalate stone disease and any type of chronic diarrhea.
Other conditions associated with enteric hyperoxaluria include fat malabsorption, steatorrhea, inflammatory bowel disease, pancreatic insufficiency, biliary cirrhosis, and short-bowel syndrome.
Urinary oxalate excretion in idiopathic or mild hyperoxaluria is usually 40-60 mg/d. Most patients with relatively mild hyperoxaluria (approximately 40-60 mg/d) have dietary hyperoxaluria.
Occasionally, oxalate poisoning is reported. Symptoms of oxalate poisoning include local irritation and systemic effects. Patients experience burning of the mouth, pharynx, and esophagus; swallowing difficulties; diarrhea; bradycardia; cardiac arrhythmia; heart failure; and renal failure. In rare cases, convulsions and unconsciousness can develop.
Severe poisoning has been caused by ingestion of the common household plant Dieffenbachia, with symptoms of severe corrosive burns of the mouth, oropharynx, esophagus, and stomach. [40]
All forms of hyperoxaluria are associated with recurrent urolithiasis.
Obtain a 24-hour urine collection and include analysis for total creatinine (ie, to determine adequacy of the collection) and other urinary chemistry components that can lead to stone formation, such as oxalate, calcium, uric acid, sodium, phosphate, and total urinary volume. Include an analysis for inhibitors of stone formation, such as potassium, citrate, and magnesium. [36]
Assess total urine volume and pH to determine the contribution of dehydration or pH to the tendency toward crystallization.
All major urinary risk factors (eg, calcium, oxalate, citrate, uric acid, total volume, sodium, phosphate, magnesium) should be periodically reassessed with 24-hour urine collection to monitor treatment efficacy, to identify new kidney stone metabolic risk factors, and to monitor patient compliance.
Repeat testing every 2-3 months while various treatment plans are used until acceptable urinary chemistry levels are reached or maximum therapy has been instituted. Thereafter, retesting every 1-2 years depending on the clinical situation is usually sufficient. The overall success of any stone preventive therapy program depends on the individual patient’s compliance with long-term preventive therapy and the continuous maintenance of an adequate urinary volume.
Obtain serum creatinine levels to evaluate renal function. Serum calcium levels may be useful in differentiating hypercalcuria from hyperparathyroidism. Tests to measure plasma oxalate levels are not currently commercially available. [37]
No specific imaging studies help to identify hyperoxaluria, but calcium oxalate nephrolithiasis can be easily diagnosed. For more information on imaging studies in the evaluation of urolithiasis, please see Nephrolithiasis: Acute Renal Colic.
Computed tomography (CT) scanning, specifically spiral CT scanning without intravenous contrast, is rapidly replacing intravenous pyelography (IVP) (see below) as the preferred method for evaluating patients with acute flank pain who may have a urinary stone.
CT scanning is faster, requires less effort, does not require any potentially hazardous intravenous contrast, and provides useful information on alternatives in the differential diagnosis. Uric acid stones show up clearly on CT scans, but stones made of protease inhibitor medications do not. Intravenous contrast can be used selectively, if needed, to clarify the diagnosis.
Limitations of CT scanning include higher cost, an inability to assess renal function, and an inability to differentiate radiopaque from radiolucent stones. In addition, the precise shape and surgical orientation of a stone can be difficult to determine based on CT scan findings alone. This can be corrected by adding kidney-ureter-bladder (KUB) radiography (see below), which helps not only to determine the size, shape, and location of the stone but also to determine its calcium content based on the degree of radiopacity.
CT scanning cannot be used in pregnant women because it is associated with more significant x-ray exposure. In addition, a small distal ureteral stone in a patient with multiple pelvic calcifications and minimal hydronephrosis may be almost impossible to identify with CT scans alone.
IVP images offer the best road map of the upper urinary tract and ureteral anatomy. They can easily reveal the precise location of stones in the urinary tract. They also provide valuable information about relative kidney function that CT scanning and ultrasonography cannot offer. Any anatomical anomalies involving urinary flow can more readily be revealed with IVP, and it often costs less than CT scanning.
Disadvantages of IVP include possible nephrotoxicity and allergy to the injected contrast agent. In general, IVP cannot be safely performed in patients whose serum creatinine level is higher than 2 mg/dL, and more time is required to perform IVP than CT scanning. The IVP provides only very limited information concerning other potential diagnoses that might mimic acute renal colic, such as abdominal aortic aneurysm, which is visualized much more easily on the CT scan.
In pregnant patients, limited IVP studies can be performed but should be minimized as much as possible.
When used in combination, renal ultrasonography and KUB radiography can be useful initial screening tools for hydronephrosis and urolithiasis. Ultrasonography is the primary diagnostic tool in pregnant patients with a suggestive renal or ureteral calculus. KUB radiography can be performed in pregnant patients but should be minimized as much as possible.
For more information on the management of kidney stones during pregnancy, see Pregnancy and Urolithiasis.
Dietary excess of oxalate-containing foods (eg, spinach, nuts, rhubarb, cranberry products) can cause hyperoxaluria. Dietary excess of vitamin C can also increase oxalate absorption and excretion, although the degree and importance of vitamin C in the development of calcium oxalate stone disease is somewhat controversial. [5]
Evaluate oral fluid intake to exclude dehydration as a component of hyperoxaluria. Fluid intake should be sufficient to generate 2000 mL or more of urine per day.
High-protein (meat) intake is known to be a significant risk factor for calcium stone disease because of its effect on urinary calcium and uric acid. A 2001 European study by Nguyen et al evaluated the effect of a diet high in meat protein on urinary oxalate in healthy subjects versus patients with idiopathic calcium stones and those with mildly hyperoxaluric calcium stones. [41]
The investigators found that approximately one third of those with idiopathic calcium stones responded to the high meat-protein intake with a significant increase in urinary oxalate excretion, while no effect was noted in healthy subjects. This suggests that, in addition to its effects on urinary calcium and uric acid levels, excessive meat-protein intake may increase urinary oxalate excretion.
Treatment of hyperoxaluria depends somewhat on the underlying etiology and severity of the hyperoxaluria. Many of the treatments mentioned can be used in any case of hyperoxaluria, and they can be combined for increased efficacy.
Initial first-line therapies include a low-oxalate diet while maintaining adequate calcium intake, pyridoxine (B-6), increased fluids, and optimization of other calcium oxalate nephrolithiasis risk factors. Limit ingestion of vitamin C and cranberry juice products. [5, 42] Calcium supplements are the initial treatment of choice for enteric hyperoxaluria, [43] along with a low-fat diet, antidiarrheal therapy, and sufficient potassium citrate supplementation to maintain optimal urinary citrate levels. Vitamin E can be safely added to any hyperoxaluria treatment regimen.
When initial treatment is insufficient to adequately control excessive urinary oxalate excretion, add orthophosphate supplementation, magnesium supplementation, or both. Both of these therapies can have adverse gastrointestinal effects; therefore, dosages should be titrated to tolerability. Phosphates are preferred in patients with hypophosphatemia or a low level of urinary pyrophosphate, while magnesium therapy is selected in patients with hypomagnesemia or hypomagnesuria.
Oxalate-binding agents such as calcium (preferred) or iron (if hypercalciuria is present) can be used. A higher dose of pyridoxine, up to 400-500 mg/d in divided doses, may also be helpful. [44]
If further treatment is necessary, cholestyramine can be added. Pentosan polysulfate (Elmiron) can be considered, although its actual effectiveness is unclear. [45, 46] Pushing fluids to increase urinary output to 3-4 L/d may be helpful. Other risk factors should be further optimized.
In cases of renal failure, intensive dialysis can be considered. Liver or combined liver-renal transplantation should be considered in patients with primary hyperoxaluria. [38, 39, 47]
Treatment for acute oxalate poisoning includes gastric lavage with a calcium solution such as 0.15% calcium hydroxide solution. Brisk diuresis is stimulated with rapid hydration to avoid calcium oxalate crystallization in the kidney. Sodium bicarbonate and sodium hydroxide should not be used because sodium oxalate is readily absorbed, increasing the systemic oxalosis effects.
Patients with primary hyperoxaluria usually present with a urinary oxalate level in excess of 100 mg/d. Early medical treatment is required to decrease the oxalate level and to prevent deterioration of renal function. Early liver-kidney transplantation is often required for definitive cure. However, the survival rates and organ survival rates in patients who undergo treatment for type I hyperoxaluria are inferior to such rates in general transplant patients. [48, 49, 50]
Dietary oxalate restrictions are of no substantial benefit in this type of hyperoxaluric disease. Several medications have been useful.
New and future treatment modalities under investigation include probiotic supplementation, [51] chaperones and hepatocyte cell transplantation, and recombinant gene therapy to replace the enzyme. [52]
Pyridoxine deficiency is known to increase urinary oxalate excretion. High-dose pyridoxine may reduce the production of oxalate by enhancing the conversion of glyoxylate to glycine, thereby reducing the substrate available for metabolism to oxalate. [4] A daily dose of 150-500 mg may be required to sufficiently reduce the oxalate level. A normal urinary oxalate level (< 40 mg/d) can be achieved in some patients. [44]
Treatment of pyridoxine-resistant primary hyperoxaluria frequently involves combinations of all available therapies and may ultimately entail renal-liver transplantation. [53]
Orthophosphate, in combination with pyridoxine, has been used effectively in the treatment of primary hyperoxaluria. Milliner et al and others have demonstrated long-term treatment benefits with this combination. [54] The phosphate increases urinary pyrophosphate and complexes with calcium, thus decreasing the urinary calcium level, while pyridoxine reduces urinary oxalate excretion.
Phosphate therapy should not be used in patients with renal failure.
Supplementation with magnesium in the form of magnesium hydroxide and magnesium oxide has been used. Magnesium can complex with oxalate in the intestinal tract, reducing the level of available free oxalate and urinary calcium oxalate supersaturation. It does not directly affect the increased endogenous production of oxalate. [23, 13]
When used in combination with pyridoxine, significant reductions in urinary oxalate levels have been noted.
It is essential to increase urinary volume. Optimal 24-hour urinary volumes of 3-4 L/d may be needed to ameliorate the effects of severe hyperoxaluria. Increasing urine volume usually requires multiple nightly disruptions of sleep for extra water consumption.
Thiazides have been shown to decrease urinary oxalate excretion somewhat, possibly by decreasing intestinal oxalate transport.
Other factors that can contribute to stone formation, such as urinary citrate and uric acid, need to be optimized.
Supplementation with glycosaminoglycans may help to reduce calcium oxalate crystallization and stone formation by reducing crystal aggregation. It also may decrease intestinal oxalate transport and urinary oxalate excretion. [55, 45, 46]
Intensive dialysis is needed in patients with primary hyperoxaluria and significant renal failure to minimize serum oxalate levels and to reduce the body stores of oxalate. The standard dialysis regimen for simple uremia is not adequate to remove sufficient oxalate to prevent stone formation or other systemic effects of oxalosis in severe hyperoxaluric states associated with renal failure. Daily hemodialysis sessions are required that last 6-8 hours per day, which is considerably more dialysis than the typical patient with end-stage renal failure needs. [56]
Removal of the native kidneys often is recommended at the time of renal transplantation because the native kidneys often have significant damage and residual stones, which makes them particularly susceptible to recurrent infections and obstruction.
Several mechanisms have been postulated to help explain the development of hyperoxaluria in patients with intestinal disease. These include increased colonic permeability, reduced free intestinal calcium available to complex with oxalate, and decreased levels of O formigenes in the intestine (which can degrade intestinal oxalate). In any event, the intestinal absorption of oxalate is markedly increased. Based on the pathophysiology, pyridoxine has only a limited beneficial effect in this condition because endogenous oxalate production is not affected.
Calcium supplementation is usually beneficial and is the preferred initial treatment option for most patients with enteric hyperoxaluria. [43] Relatively severe hypocalciuria due to calcium binding to nonabsorbed fatty acids, with eventual loss in feces, usually accompanies enteric hyperoxaluria; therefore, the supplemental calcium is unlikely to cause a hypercalciuric state. In addition, calcium supplementation may be beneficial in sustaining bone mass. Supplemental calcium binds strongly to any free intestinal oxalate, preventing absorption.
The most commonly recommended form is calcium citrate because the citrate component offers an additional benefit as a natural inhibitor of calcium oxalate urinary crystallization. Calcium citrate without vitamin D should be used because the calcium should remain in the intestinal tract as long as possible to better interact and bind with the available oxalate. Calcium carbonate can also be used but does not have the same beneficial effect as citrate.
Iron can act as a substitute intestinal oxalate-binding agent. Experiments in rats have demonstrated its effectiveness, although calcium is the preferred oxalate-binding agent whenever possible.
Aluminum can also limit oxalate absorption through intestinal binding, but the danger of aluminum toxicity is a concern.
Magnesium also binds free intestinal oxalate and can prevent its absorption; however, magnesium may cause diarrhea in patients with inflammatory bowel disease. This may lead to subsequent stone-promoting effects such as lower urinary pH, decreased urinary volume, and hypocitraturia. [13]
Oxalate transport in the proximal renal tubule is indirectly coupled with an Na/H exchanger, which suggests that urinary alkalinization with potassium citrate may reduce urinary oxalate excretion. This has been shown to occur in an animal model, suggesting an additional possible benefit of potassium citrate therapy in patients with calcium oxalate stones.
Potassium citrate in dosages of 40-60 mEq/d in divided doses is beneficial to increase the urinary pH and citrate level. This is particularly helpful in patients with significant diarrhea or hypocitraturia. If the diarrhea can be controlled, the potassium citrate dosage may need to be modified. Control of diarrhea should be a priority whenever possible. Reversal of jejunoileal bypass surgery is sometimes necessary to correct this problem.
Cholestyramine is a nonabsorbable anion exchange resin that selectively binds bile salts, fatty acids, and intestinal oxalate. It can also help reduce the diarrhea associated with enteric hyperoxaluria.
Cholestyramine is available as a dry powder that needs to be mixed with 60-180 mL of water, juice, milk, or other noncarbonated beverages. Preparing the mixture in advance and keeping it refrigerated sometimes helps make it more palatable. Alternatively, crushed pineapple or applesauce can be used as a vehicle for the medication. The usual dosage is 1-4 g 3-4 times daily with meals.
The main adverse effect of cholestyramine is constipation. Dosages larger than 24 g/d are discouraged because they tend to cause steatorrhea. Because chloride is released from the resin, hyperchloremic acidosis is a potential complication. Cholestyramine interferes with the absorption of many other medications, especially thiazide diuretics. If used together, they should be given at widely separated intervals.
Patients on long-term therapy may need fat-absorbable vitamin supplements (vitamin A and folic acid), and cholestyramine use may slightly increase the risk of vitamin K deficiency.
Diets containing reduced amounts of fat, meat protein, and oxalate are helpful if the patient can tolerate and sustain them. [57] In particular, a low-fat diet helps both the hyperoxaluria and the chronic diarrhea that accompanies enteric hyperoxaluria. The low-fat diet has minimal effect on other types of hyperoxaluria, although it can be recommended for other health reasons.
Increased fluid intake to expand urinary volume is also recommended, not only to restore fluid lost through the digestive tract but also to act as a dilutional inhibitor of crystal and stone formation.
Organic marine hydrocolloid (OMH) is a high-molecular-weight polymer extracted from plants and seaweed. It was found to be helpful in one study on patients with enteric hyperoxaluria, as reported by Lindsjo and colleagues. [58]
A specially processed OMH charged with calcium and zinc was able to reduce urinary oxalate by an average of more than 20%. Stone production declined, and chronic diarrhea was improved in 70% of patients. While the study had a very limited number of patients, their clinical enteric hyperoxaluria situation was severe.
Mild hyperoxaluria (40-60 mg/d) occurs in 5-50% of patients with stones who have no other medical conditions. After hypercalciuria, it is the most commonly identified metabolic abnormality found in patients with recurrent stone formation.
This is an important aspect of management in this group. Foods that contain high oxalate levels (eg, spinach, rhubarb, beets, nuts, chocolate, tea, wheat bran, strawberries) should be avoided, while moderate calcium intake in the form of dairy products should be encouraged. Even foods with only a moderate amount of oxalate may need to be limited if large amounts are frequently ingested. Long-term dietary oxalate restriction has not been shown to have any deleterious effects. Increased fluid intake and a low-fat low–meat-protein diet are also suggested.
A lack of response to dietary measures alone may indicate either increased intestinal oxalate transport or inherent endogenous overproduction that may respond to pyridoxine in a manner similar to cases of primary hyperoxaluria.
Pyridoxine has been investigated and found to be helpful in many cases, but dosages up to 400-500 mg/d may be needed. Approximately 50% of patients respond to pyridoxine treatment. For unknown reasons, pyridoxine therapy for hyperoxaluria seems to be more beneficial in women than in men. [44]
Other measures, such as phosphate or magnesium supplementation, can also be used. Combination therapy of pyridoxine with magnesium, oral phosphates, or both has been shown to be efficacious in reducing stone recurrences and urinary oxalate excretion. [53, 13, 59]
Excessive vitamin C ingestion should be avoided because of the potential for its conversion into oxalate. [5]
Although it is unclear whether vitamin E has any efficacy in hyperoxaluric humans, adding this therapy to the treatment regimen is of little risk. [60, 61]
Calcium supplementation with calcium citrate to increase intestinal oxalate binding is rarely necessary to control stone production. [43]
Cholestyramine is rarely needed to control nephrolithiasis in these relatively mild cases of hyperoxaluria.
Glycosaminoglycan supplementation may be of some benefit in preventing calcium oxalate stone formation when other methods are insufficiently effective and stone production continues. Preventing calcium oxalate crystal aggregation is probably the most significant effect of pentosan polysulfate, although it may also have some limited direct beneficial effect on intestinal oxalate transport. [55, 45, 46]
Although often recommended for urinary tract symptoms and urinary tract infections (UTIs), cranberry juice and tablets can increase urinary oxalate by as much as 40% or more because of their relatively high oxalate content and should be avoided. [42]
Excessive meat-protein intake should be avoided because it has been shown to significantly increase urinary oxalate excretion in approximately one third of all patients with idiopathic calcium kidney stones.
As with other patients with stones, adequate fluid intake and a low-salt and low-protein diet should be encouraged. Ideally, sufficient fluid intake to maintain a urinary output of more than 2 L/d is important, especially in patients with chronic diarrheal states due to intestinal disease. Patients with severe hyperoxaluria may need to achieve a daily urinary output of 3 or even 4 L/d to avoid stone formation. [62]
Patients with enteric and idiopathic hyperoxaluria should avoid oxalate-rich foods such as spinach, tea, chocolate, strawberries, nuts, and peanut butter (see the image below). Furthermore, dietary calcium intake through dairy products should be maintained to decrease urinary oxalate levels. Ascorbic acid may be converted to oxalate in the oxalate metabolic pathway; therefore, the use of ascorbic acid–containing medications should be avoided.
Surgical interventions that may be indicated include lithotripsy and renal-liver transplantation.
The principles of surgical management in patients with stones who also have hyperoxaluria do not differ from the management principles in other patients with urolithiasis. These patients form calcium oxalate stones that can be monohydrate or dihydrate in nature. Calcium oxalate monohydrate calculi are one of the hardest stone types to fragment with current lithotripsy modalities and may require multiple treatments based on size and location.
Extracorporeal shockwave lithotripsy can be used for renal and ureteral calculi. Intracorporeal lithotripsy using electrohydraulic, pneumatic (Lithoclast), ultrasonic, and holmium laser modalities can all be successful in the management of ureteral and large-burden renal calculi. Ureteroscopic or percutaneous access is required in these cases.
Young patients with primary hyperoxaluria may develop renal failure due to nephrocalcinosis. Renal transplantation alone is associated with recurrent stone formation attributable to the persistence of abnormal glyoxylate metabolism in the liver. Therefore, a combined renal-liver transplantation is necessary and should be performed as early as possible to achieve cure.
In selected patients, early liver transplantation prior to the development of overt renal failure may preserve the native kidneys, thus avoiding renal transplantation. [39] In general, transplantation is considered when the glomerular filtration rate (GFR) falls to below 25 mL/min/1.73 m2. [63] Renal transplantation alone is insufficient because the liver defect causing the hyperoxaluria is not corrected.
Consultation with a general surgeon may be required in cases of primary hyperoxaluria if liver transplantation is indicated. [39] Patients with enteric hyperoxaluria also may require a consultation with a general surgeon.
Other consultations with a medical specialist may be indicated for follow-up care in the treatment of patients with bowel disease and primary hyperoxaluria. A pediatrician should be involved in the care of children with primary hyperoxaluria or any serious oxalate problem.
Consultation with a dietitian may help in the diagnosis of dietary excess of oxalate and for counseling patients regarding foods to avoid.
O formigenes is a facultative anaerobic bacteria normally found primarily in the colon, and it digests oxalate within the intestinal tract. The intestinal tract is normally colonized with Oxalobacter at approximately age 3 years. Oxalobacter loss is primarily due to prolonged or repeated antibiotic therapy. [22] Fluoroquinolones, cephalosporins, tetracyclines, and macrolide preparations are particularly toxic to Oxalobacter bacteria, while penicillin and sulfa drugs have relatively little effect. [64, 65]
O formigenes is found in 70-80% of all adults but is missing or depleted in more than 60% of patients with hyperoxaluria. Patients with multiple episodes of calcium oxalate stone disease (4 or more separate incidents) are even less likely to have normal Oxalobacter colonies, with 80-90% demonstrating reduced colonization. Urinary oxalate excretion in patients with calcium oxalate stones who have lost their Oxalobacter colonies is typically 40% higher than in their counterparts with normal Oxalobacter levels.
Female patients with stones who have recurrent UTIs and undergo multiple courses of antibiotic therapy tend to be deficient in Oxalobacter and have significantly higher average urinary oxalate levels than similar patients without a history of recurrent urinary tract infections (UTIs).
A study by Siener et al found that average urinary oxalate levels in women with calcium oxalate stones who have recurrent UTIs were almost 18% higher than in women with calcium oxalate stones who did not have a history of UTI. [66] This is most likely due to the effect of repeated courses of antibiotics on intestinal Oxalobacter.
A similar result was found by Sidhu et al in a group of patients with cystic fibrosis (CF), who frequently receive prolonged and repeated courses of antibiotics. [67, 68] In this study, all patients with CF who had active intestinal Oxalobacter colonies had normal urinary oxalate levels, while more than 50% of patients with CF who were found to be deficient in Oxalobacter were hyperoxaluric.
Despite promising preliminary data, there has been no evidence from controlled trials to further support the use of oral O. formigenes therapy in primary hyperoxaluria. In 2017, two controleed trials reported that although the treatment was well tolerated and successfully delivered to the gastrointestinal tract, neither trial could demonstrate a significant reduction in either urinary oxalate excretion or plasma oxalate concentration compared to placebo. [69, 70] Furthermore, no studies using oral O. formigenes in groups of patients with enteric or idiopathic hyperoxaluria have yet appeared in the literature. Thus, the role of pharmacologic use of this bacteria to reduce urinary oxalate excretion, and hence kidney stone risk, remains to be determined.
Banana stem juice has been suggested as a possible treatment for hyperoxaluria. While it appeared to be of benefit in animal studies, to date, no human testing has been performed. [71]
Ramakrishnan et al described a plant-based (ie, beet stem) oxalate-digesting enzyme has that may prove to be useful in the treatment of hyperoxaluria in the future. [72]
Lupeol is a pentacyclic triterpene that is extracted from Crataeva nurvala stem bark. It has shown oxalate-reducing activity and is able to significantly reduce the renal excretion of oxalate in an animal model. [73] It also reduces renal tubular damage, presumably through decreased calcium oxalate crystallization.
RNA interference (RNAi) is a naturally occurring cellular mechanism for regulating gene expression mediated by small interfering RNAs (siRNAs). Synthetic siRNAs can be designed to target the endogenous mRNA transcript of a given gene, leading to its cleavage and the subsequent suppression of synthesis of the encoded protein. There have been reports of the possible therapeutic benefit of RNAi therapeutics in the treatment of primary hyperoxaluria in mouse models. [74, 75, 76]
L -cysteine has shown some beneficial activity by significantly lowering urinary oxalate and calcium levels while increasing urinary citrate and magnesium levels in an animal model. [77, 23]
Vitamin E supplementation has been suggested to be of some value in reducing calcium oxalate crystallization, but the usefulness of this therapy in humans remains unproven. [60, 61]
A specific inhibitor of renal tubular oxalate secretion, which reduced urinary oxalate levels by 20% in an animal model, has been described. [78, 79]
Various antioxidant therapies may provide some protection to the delicate proximal renal tubular cells that are very prone to injury from calcium oxalate crystal formation. This may help limit calcium oxalate stone formation.
The manufacturer of Oxadrop, which is a combination of 5 different lactic acid bacteria, has claimed that the product can significantly reduce urinary oxalate excretion. Unfortunately, randomized studies have shown no effect. [80, 81]
These and other experimental therapies will continue to be studied until better and more effective remedies for hyperoxaluria are developed.
Cochat P. Primary hyperoxaluria type 1. Kidney Int. 1999 Jun. 55(6):2533-47. [Medline].
Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009 Jun. 75(12):1264-71. [Medline].
Mukhin VN, Khomiakov KA. [Phenogenetics of offspring and their ancestors]. Tsitol Genet. 2003 Jul-Aug. 37(4):54-6. [Medline].
Holmes RP, Assimos DG. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J Urol. 1998 Nov. 160(5):1617-24. [Medline].
Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol. 1999 Apr. 10(4):840-5. [Medline].
Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 2010 Mar. 77(5):443-9. [Medline].
Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010 Sep 10. 87(3):392-9. [Medline]. [Full Text].
Belostotsky R, Pitt JJ, Frishberg Y. Primary hyperoxaluria type III–a model for studying perturbations in glyoxylate metabolism. J Mol Med (Berl). 2012 Dec. 90(12):1497-504. [Medline].
Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet. 2013 Feb. 21(2):162-72. [Medline]. [Full Text].
Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011 Sep. 6(9):2289-95. [Medline]. [Full Text].
Milliner DS, Harris PC, Lieske JC, Pagon RA, Adam MP, Ardinger HH, et al. Primary Hyperoxaluria Type 3. 1993. [Medline]. [Full Text].
Lumlertgul N, Siribamrungwong M, Jaber BL, Susantitaphong P. Secondary Oxalate Nephropathy: A Systematic Review. Kidney Int Rep. 2018 Nov. 3 (6):1363-1372. [Medline]. [Full Text].
Su CJ, Shevock PN, Khan SR, Hackett RL. Effect of magnesium on calcium oxalate urolithiasis. J Urol. 1991 May. 145(5):1092-5. [Medline].
Brändle E, Bernt U, Hautmann RE. In situ characterization of oxalate transport across the basolateral membrane of the proximal tubule. Pflugers Arch. 1998 May. 435(6):840-9. [Medline].
Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007 Feb. 177(2):565-9. [Medline].
Whitson JM, Stackhouse GB, Stoller ML. Hyperoxaluria after modern bariatric surgery: case series and literature review. Int Urol Nephrol. 2010 Jun. 42(2):369-74. [Medline]. [Full Text].
Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001 Jan. 59(1):270-6. [Medline].
Khan SR, Glenton PA, Byer KJ. Dietary oxalate and calcium oxalate nephrolithiasis. J Urol. 2007 Nov. 178(5):2191-6. [Medline].
Massey LK, Roman-Smith H, Sutton RA. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. J Am Diet Assoc. 1993 Aug. 93(8):901-6. [Medline].
Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol. 1999 Nov. 10 Suppl 14:S334-40. [Medline].
Troxel SA, Sidhu H, Kaul P, Low RK. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate. J Endourol. 2003 Apr. 17(3):173-6. [Medline].
Kwak C, Jeong BC, Lee JH, Kim HK, Kim EC, Kim HH. Molecular identification of Oxalobacter formigenes with the polymerase chain reaction in fresh or frozen fecal samples. BJU Int. 2001 Oct. 88(6):627-32. [Medline].
Liebman M, Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol. 2000 May. 163(5):1565-9. [Medline].
Baggio B, Gambaro G, Marchini F, Cicerello E, Tenconi R, Clementi M, et al. An inheritable anomaly of red-cell oxalate transport in “primary” calcium nephrolithiasis correctable with diuretics. N Engl J Med. 1986 Mar 6. 314(10):599-604. [Medline].
Lewandowski S, Rodgers A, Schloss I. The influence of a high-oxalate/low-calcium diet on calcium oxalate renal stone risk factors in non-stone-forming black and white South African subjects. BJU Int. 2001 Mar. 87(4):307-11. [Medline].
Rodgers AL, Lewandowski S. Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups. J Urol. 2002 Sep. 168(3):931-6. [Medline].
Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. J Urol. 1997 Dec. 158(6):2221-4. [Medline].
Goldfarb DS, Parks JH, Coe FL. Renal stone disease in older adults. Clin Geriatr Med. 1998 May. 14(2):367-81. [Medline].
Wood KD, Holmes RP, Knight J. RNA interference in the treatment of renal stone disease: Current status and future potentials. Int J Surg. 2016 Dec. 36 (Pt D):713-716. [Medline]. [Full Text].
Clifford-Mobley O, Hewitt L, Rumsby G. Simultaneous analysis of urinary metabolites for preliminary identification of primary hyperoxaluria. Ann Clin Biochem. 2015 Sep 4. [Medline].
Iguchi M, Takamura C, Umekawa T, Kurita T, Kohri K. Inhibitory effects of female sex hormones on urinary stone formation in rats. Kidney Int. 1999 Aug. 56(2):479-85. [Medline].
Fan J, Chandhoke PS, Grampsas SA. Role of sex hormones in experimental calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1999 Nov. 10 Suppl 14:S376-80. [Medline].
Lee YH, Huang WC, Chiang H, Chen MT, Huang JK, Chang LS. Determinant role of testosterone in the pathogenesis of urolithiasis in rats. J Urol. 1992 Apr. 147(4):1134-8. [Medline].
Fan J, Glass MA, Chandhoke PS. Effect of castration and finasteride on urinary oxalate excretion in male rats. Urol Res. 1998. 26(1):71-5. [Medline].
Powell CR, Stoller ML, Schwartz BF, Kane C, Gentle DL, Bruce JE, et al. Impact of body weight on urinary electrolytes in urinary stone formers. Urology. 2000 Jun. 55(6):825-30. [Medline].
Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int. 2001 Jun. 59(6):2290-8. [Medline].
Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 1999 Jul. 56(1):268-74. [Medline].
Kemper MJ. Concurrent or sequential liver and kidney transplantation in children with primary hyperoxaluria type 1?. Pediatr Transplant. 2005 Dec. 9(6):693-6. [Medline].
Nolkemper D, Kemper MJ, Burdelski M, Vaismann I, Rogiers X, Broelsch CE, et al. Long-term results of pre-emptive liver transplantation in primary hyperoxaluria type 1. Pediatr Transplant. 2000 Aug. 4(3):177-81. [Medline].
Drach G, Malone W. Toxicity of common houseplant. JAMA. 1963. 184:1047-8.
Nguyen QV, Kälin A, Drouve U, Casez JP, Jaeger P. Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone formers. Kidney Int. 2001 Jun. 59(6):2273-81. [Medline].
Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology. 2001 Jan. 57(1):26-9. [Medline].
Takei K, Ito H, Masai M, Kotake T. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Urol Int. 1998. 61(3):192-5. [Medline].
Mitwalli A, Ayiomamitis A, Grass L, Oreopoulos DG. Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. Int Urol Nephrol. 1988. 20(4):353-9. [Medline].
Senthil D, Malini MM, Varalakshmi P. Sodium pentosan polysulphate–a novel inhibitor of urinary risk factors and enzymes in experimental urolithiatic rats. Ren Fail. 1998 Jul. 20(4):573-80. [Medline].
Senthil D, Subha K, Saravanan N, Varalakshmi P. Influence of sodium pentosan polysulphate and certain inhibitors on calcium oxalate crystal growth. Mol Cell Biochem. 1996 Mar 9. 156(1):31-5. [Medline].
Kotb MA, Hamza AF, Abd El Kader H, El Monayeri M, Mosallam DS, Ali N, et al. Combined liver-kidney transplantation for primary hyperoxaluria type I in children: Single Center Experience. Pediatr Transplant. 2018 Nov 26. e13313. [Medline].
Cochat P, Basmaison O. Current approaches to the management of primary hyperoxaluria. Arch Dis Child. 2000 Jun. 82(6):470-3. [Medline]. [Full Text].
Milliner D. Treatment of the primary hyperoxalurias: a new chapter. Kidney Int. 2006 Oct. 70(7):1198-200. [Medline].
Pais VM Jr, Assimos DG. Pitfalls in the management of patients with primary hyperoxaluria: a urologist’s perspective. Urol Res. 2005 Nov. 33(5):390-3. [Medline].
Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 2005 Sep. 68(3):1244-9. [Medline].
Straub M, Hautmann RE, Hesse A, Rinnab L. [Calcium oxalate stones and hyperoxaluria. What is certain? What is new?]. Urologe A. 2005 Nov. 44(11):1315-23. [Medline].
Rattan V, Sidhu H, Vaidyanathan S, Thind SK, Nath R. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers. Urol Res. 1994. 22(3):161-5. [Medline].
Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med. 1994 Dec 8. 331(23):1553-8. [Medline].
Erturk E, Kiernan M, Schoen SR. Clinical association with urinary glycosaminoglycans and urolithiasis. Urology. 2002 Apr. 59(4):495-9. [Medline].
Bobrowski AE, Langman CB. Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother. 2006 Oct. 7(14):1887-96. [Medline].
Asplin JR. The management of patients with enteric hyperoxaluria. Urolithiasis. 2016 Feb. 44 (1):33-43. [Medline].
Lindsjö M, Fellström B, Ljunghall S, Wikström B, Danielson BG. Treatment of enteric hyperoxaluria with calcium-containing organic marine hydrocolloid. Lancet. 1989 Sep 23. 2(8665):701-4. [Medline].
Bollée G, Cochat P, Daudon M. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health Dis. 2015. 2:31. [Medline].
Adhirai M, Selvam R. Effect of cyclosporin on liver antioxidants and the protective role of vitamin E in hyperoxaluria in rats. J Pharm Pharmacol. 1998 May. 50(5):501-5. [Medline].
Selvam R, Ravichandran V. Restoration of tissue antioxidants and prevention of renal stone deposition in vitamin B6 deficient rats fed with vitamin E or methionine. Indian J Exp Biol. 1993 Nov. 31(11):882-7. [Medline].
Liebman M, Chai W. Effect of dietary calcium on urinary oxalate excretion after oxalate loads. Am J Clin Nutr. 1997 May. 65(5):1453-9. [Medline].
Moreira DM, Friedlander JI, Hartman C, Gershman B, Smith AD, Okeke Z. Association of estimated glomerular filtration rate with 24-h urinalysis and stone composition. Urolithiasis. 2015 Nov 16. [Medline].
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006 Oct. 70(7):1305-11. [Medline].
Hoppe B, von Unruh G, Laube N, Hesse A, Sidhu H. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?. Urol Res. 2005 Nov. 33(5):372-5. [Medline].
Siener R, Ebert D, Hesse A. Urinary oxalate excretion in female calcium oxalate stone formers with and without a history of recurrent urinary tract infections. Urol Res. 2001 Aug. 29(4):245-8. [Medline].
Sidhu H, Hoppe B, Hesse A, Tenbrock K, Brömme S, Rietschel E, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet. 1998 Sep 26. 352(9133):1026-9. [Medline].
Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, et al. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis. 2005 Sep. 46(3):440-5. [Medline].
Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van’t Hoff W, et al. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr Nephrol. 2017 May. 32 (5):781-790. [Medline].
Milliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis. 2017 Jul 17. [Medline].
Poonguzhali PK, Chegu H. The influence of banana stem extract on urinary risk factors for stones in normal and hyperoxaluric rats. Br J Urol. 1994 Jul. 74(1):23-5. [Medline].
Ramakrishnan V, Lathika KM, D’Souza SJ, Singh BB, Raghavan KG. Investigation with chitosan-oxalate oxidase-catalase conjugate for degrading oxalate from hyperoxaluric rat chyme. Indian J Biochem Biophys. 1997 Aug. 34(4):373-8. [Medline].
Malini MM, Baskar R, Varalakshmi P. Effect of lupeol, a pentacyclic triterpene, on urinary enzymes in hyperoxaluric rats. Jpn J Med Sci Biol. 1995 Oct-Dec. 48(5-6):211-20. [Medline].
Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, et al. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Biochim Biophys Acta. 2016 Feb. 1862 (2):233-9. [Medline]. [Full Text].
Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, et al. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1. Mol Ther. 2016 Apr. 24 (4):770-8. [Medline]. [Full Text].
Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, et al. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol. 2017 Feb. 28 (2):494-503. [Medline]. [Full Text].
Saravanan N, Senthil D, Varalakshmi P. Effect of L-cysteine on some urinary risk factors in experimental hyperoxaluric rats. Br J Urol. 1996 Jul. 78(1):22-4. [Medline].
Brandle E, Bernt U, Kleinschmidt K. EO8 a specific inhibitor of the renal tubular oxalate secretion – a new concept in the medical treatment of calcium oxalate stones. J Urol. 1999. 161(4):248.
Straub M, Befolo-Elo J, Hautmann R, et al. Does the renal-tubular oxalate excretion depend on urinary-pH?. J Urol. 2002. 167(4):257-8.
Goldfarb DS, Modersitzki F, Asplin JR. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol. 2007 Jul. 2(4):745-9. [Medline].
Lieske JC. Probiotics for prevention of urinary stones. Ann Transl Med. 2017 Jan. 5 (2):29. [Medline]. [Full Text].
Bijan Shekarriz, MD Director, Laparoscopy and Minimally Invasive Surgery, Associate Professor of Urology, Department of Urology, State University of New York Upstate Medical University
Bijan Shekarriz, MD is a member of the following medical societies: American Urological Association, Endourological Society
Disclosure: Nothing to disclose.
Marshall L Stoller, MD Professor and Vice Chairman, Medical Director of Urinary Stone Center, Department of Urology, University of California, San Francisco, School of Medicine
Marshall L Stoller, MD is a member of the following medical societies: American Urological Association
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine
Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, Society of University Urologists
Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Cook Medical; Olympus.
Martha K Terris, MD, FACS Professor, Department of Surgery, Section of Urology, Director, Urology Residency Training Program, Medical College of Georgia at Augusta University; Professor, Department of Physician Assistants, Medical College of Georgia School of Allied Health; Chief, Section of Urology, Augusta Veterans Affairs Medical Center
Martha K Terris, MD, FACS is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Institute of Ultrasound in Medicine, American Society of Clinical Oncology, American Urological Association, Association of Women Surgeons, New York Academy of Sciences, Society of Government Service Urologists, Society of University Urologists, Society of Urology Chairpersons and Program Directors, Society of Women in Urology
Disclosure: Nothing to disclose.
Hyperoxaluria
Research & References of Hyperoxaluria |A&C Accounting And Tax Services
Source